Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:52:25.418Z.
Calculation as of: 2026-10-06T22:52:25.418Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64600f38e310d2eb3cd81a0b95bf77f6abd31b9de5548b9cdd3f3c9d46967593
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
PROCEPT BioRobotics Corporation
Market Cap
$996.65M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.69M
EV/EBITDA Ratio
N/A
TTM Avg
2.11x
3Y Avg
2.11x
5Y Avg
2.11x
Market Cap
$982.46M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
EV/EBITDA Ratio
4.84x
TTM Avg
6.06x
3Y Avg
6.06x
5Y Avg
6.06x
Market Cap
$978.09M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
EV/EBITDA Ratio
N/A
TTM Avg
56.92x
3Y Avg
58.14x
5Y Avg
58.14x
Market Cap
$973.93M
EV/EBITDA Ratio
11.39x
TTM Avg
10.94x
3Y Avg
46.55x
5Y Avg
35.86x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $996.65M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | N/A | 2.11x | 2.11x | 2.11x |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 21.42x | 21.42x | 21.42x |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 4.84x | 6.06x | 6.06x | 6.06x |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | N/A | 56.92x | 58.14x | 58.14x |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 11.39x | 10.94x | 46.55x | 35.86x |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
